CRDF
Cardiff Oncology, Inc.
Biotechnology · Healthcare · United States
0.89
close · 2026-10-30
value
4
cheaper than peers4
quality
22
stronger fundamentals22
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.30× | 66 |
| cash flow yield, 2 years ago | -45.5% | 21 |
| cash flow yield, 3 years ago | -50.3% | 19 |
| earnings yield, 3 years ago | -100.0% | 16 |
| cash flow yield, 1 year ago | -54.6% | 15 |
| earnings yield, 2 years ago | -104.5% | 14 |
| cash flow yield, latest year | -54.9% | 14 |
| earnings yield, 1 year ago | -106.8% | 14 |
| earnings yield, latest year | -77.6% | 12 |
| price to sales | 136.23× | 10 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.7% | 88 |
| revenue growth | -14.1% | 28 |
| return on equity | -94.1% | 28 |
| operating margin | -9245.2% | 1 |
4 of 4 measures available
Facts
| market cap | $69M |
| free cash flow | -$24.3M |
| employees | 30 |
| first trade | 2004-07-27 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-08-17 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.69 | -0.95 | -0.93 | -0.89 | not reported |
| free cash flow | -$38.0M | -$37.8M | -$31.5M | -$34.8M | not reported |
| net income | -$45.9M | -$45.4M | -$41.4M | -$38.7M | not reported |
| revenue | $593,000 | $683,000 | $488,000 | $386,000 | not reported |
| unusual items | not reported | not reported | not reported | not reported | $285,000 |